Koers Viracta Therapeutics, Inc. Nasdaq
Aandelen
US92765F1084
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | - | Omzet 2025 * | 2,33 mln. 2,18 mln. | Marktkapitalisatie | 32,24 mln. 30,07 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -62 mln. -57,83 mln. | Nettowinst (verlies) 2025 * | -86 mln. -80,21 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 13,8 x |
K/w-verhouding 2024 * |
-0,71
x | K/w-verhouding 2025 * |
-0,73
x | Werknemers | 40 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 97,08% |
Recentste transcriptie over Viracta Therapeutics, Inc.
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Mark Rothera
CEO | Chief Executive Officer | 62 | 19-09-22 |
Melody Burcar
DFI | Director of Finance/CFO | 41 | 01-09-22 |
Chief Tech/Sci/R&D Officer | - | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Ivor Royston
BRD | Director/Board Member | 79 | 01-10-07 |
Thomas Darcy
BRD | Director/Board Member | 74 | 01-02-21 |
Barry Simon
BRD | Director/Board Member | 69 | 03-03-21 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+1,77% | 42,86 mld. | |
+44,64% | 41,36 mld. | |
+12,24% | 42,74 mld. | |
-8,83% | 27,68 mld. | |
+7,44% | 25,15 mld. | |
-23,01% | 18,63 mld. | |
+30,56% | 12,37 mld. | |
-1,82% | 11,92 mld. | |
+8,35% | 11,21 mld. |